JAK1/2 inhibitor. Dysregulated JAK-STAT pathway in CTCL leads to T-cell activation. Phase II trial showed 23% ORR. The gene discussed is SOAT1; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.